WaveMan
WaveMan · Company
BBNX · Beta Bionics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

BBNX Beta Bionics (BBNX) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001674632
Quote by TradingView
Form 144 · 11
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
87
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $76.4K priced

What the filings say about BBNX

Insiders, 180 days
-$3.8M net sold
7 sellers · 25% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$2.5M
11 notices

Beta Bionics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Beta Bionics, Inc. insiders sold a net $3.8M of stock across 86 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Hopman Mark
Chief Commercial Officer
SELL
2026-10-16 SECtraded 2026-10-14
775
$13.4K
+27.0%
Context
  • 20 earlier Form 4 trades (code P or S) here by this insider (20 sales), the last on Oct 1, 2026.
  • The trade is 1.4% of the 55,334 shares held after it.
  • 2 other insiders sold within 30 days.
  • 87 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Hopman Mark sold about $13.4K of BBNX on Oct 14, 2026; 2 other insiders sold within 30 days and 87 funds added in the latest 13F quarter.
Hopman Mark
Chief Commercial Officer
SELL
2026-10-05 SECtraded 2026-10-01
370
$7.0K
+14.8%
Context
  • 19 earlier Form 4 trades (code P or S) here by this insider (19 sales), the last on Sep 16, 2026.
  • The trade is 0.7% of the 56,109 shares held after it.
  • 5 other insiders sold within 30 days.
  • 87 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Hopman Mark sold about $7.0K of BBNX on Oct 1, 2026; 5 other insiders sold within 30 days and 87 funds added in the latest 13F quarter.
Jones Christy
Director
SELL
2026-09-23 SECtraded 2026-09-22
6,430
$147.9K
-1.7%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Jun 24, 2026.
  • The trade is 32.9% of the 19,564 shares held after it.
  • 5 other insiders sold within 30 days.
  • 87 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Jones Christy sold about $147.9K of BBNX under a 10b5-1 plan on Sep 22, 2026; 5 other insiders sold within 30 days and 87 funds added in the latest 13F quarter.
Hopman Mark
Chief Commercial Officer
SELL
2026-09-17 SECtraded 2026-09-16
30,779
$619.6K
-2.3%
Context
  • 18 earlier Form 4 trades (code P or S) here by this insider (18 sales), the last on Sep 14, 2026.
  • The trade is 54.5% of the 56,479 shares held after it.
  • 5 other insiders sold within 30 days.
  • 87 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Hopman Mark sold about $619.6K of BBNX under a 10b5-1 plan on Sep 16, 2026; 5 other insiders sold within 30 days and 87 funds added in the latest 13F quarter.
Mensinger Mike
Chief Product Officer
SELL
2026-09-17 SECtraded 2026-09-16
2,650
$58.3K
-2.3%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (1 buy, 12 sales), the last on Sep 2, 2026.
  • The trade is 1.5% of the 177,390 shares held after it.
  • 5 other insiders sold within 30 days.
  • 87 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Product Officer Mensinger Mike sold about $58.3K of BBNX under a 10b5-1 plan on Sep 16, 2026; 5 other insiders sold within 30 days and 87 funds added in the latest 13F quarter.
86 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 81 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$3.8M over 180 days
-$3.0M over 90 days
below 74% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
87 funds bought in last quarter
more than 61% of Medical Devices
Revenue
+53.9% year over year
more than 88% of Medical Devices
Margin
-73.0% net margin
below 76% of Medical Devices
Buybacks
no share repurchases reported
Short interest
19.4% of the float short (float per yahoo 2026-10-26) · 3.2 days to cover · settled 2026-09-30
more than 95% of Medical Devices
What changed in the last 30 days
Oct 16Chief Commercial Officer Hopman Mark sold $20.5K (2 trades, Oct 1 to Oct 14)
Oct 1Officer MARK HOPMAN filed to sell $50.5K by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch BBNX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+6.9%12M
-56%-17%+21%+60%2025-102025-122026-022026-042026-062026-082026-10 2026-09-09 · Hopman Mark sold $680.7K2026-09-09 · Hopman Mark sold $664.6K2026-09-16 · Hopman Mark sold $619.6K2026-01-02 · Feider Stephen sold $590.6K2026-09-02 · Saint Sean sold $322.4K2026-01-02 · Mensinger Mike sold $212.8K2026-06-02 · Saint Sean sold $212.8K2026-09-22 · Jones Christy sold $147.9K2026-09-02 · Feider Stephen sold $127.6K2026-09-03 · Saint Sean sold $113.3K2026-09-02 · Hopman Mark sold $101.8K2025-12-02 · Saint Sean sold $96.2K2026-06-26 · Feider Stephen sold $87.0K2026-06-02 · Feider Stephen sold $84.2K2026-09-02 · Mensinger Mike sold $83.6K2026-06-29 · Feider Stephen sold $83.4K2026-09-02 · Russell Steven Jon sold $80.7K2026-06-02 · Hopman Mark sold $67.2K2026-01-06 · Mensinger Mike sold $66.2K2025-12-04 · Hopman Mark sold $63.2K2026-09-16 · Mensinger Mike sold $58.3K2026-06-02 · Mensinger Mike sold $55.2K2026-06-02 · Russell Steven Jon sold $53.2K2025-12-02 · Feider Stephen sold $41.9K2026-03-02 · Saint Sean sold $41.8K2026-06-04 · Jones Christy sold $39.4K2025-10-31 · Lezack Adam sold $36.7K2025-10-31 · Palasis Maria sold $34.6K2025-12-02 · Mensinger Mike sold $31.2K2025-12-02 · Russell Steven Jon sold $30.1K2025-12-01 · Lezack Adam sold $26.6K2025-12-01 · Palasis Maria sold $26.6K2025-12-02 · Hopman Mark sold $25.1K2026-06-24 · Jones Christy sold $21.1K2026-05-21 · Jones Christy sold $19.9K2026-06-24 · Hopman Mark sold $18.9K2026-01-02 · Mensinger Mike sold $18.1K2026-03-02 · Feider Stephen sold $17.7K2025-12-01 · Palasis Maria sold $15.0K2025-12-01 · Lezack Adam sold $15.0K2026-10-14 · Hopman Mark sold $13.4K2026-03-02 · Mensinger Mike sold $13.2K2026-10-01 · MARK HOPMAN filed to sell $50.5K2026-09-22 · CHRISTINA JONES filed to sell $197.1K2026-09-16 · MARK HOPMAN filed to sell $540.7K2026-09-16 · MICHAEL MENSINGER filed to sell $101.9K2026-09-09 · MARK HOPMAN filed to sell $779.1K2026-09-03 · Sean Saint filed to sell $113.3K2026-09-03 · Mark Hopman filed to sell $103.4K2026-09-03 · Michael R. Mensinger filed to sell $84.9K2026-09-03 · Stephen Feider filed to sell $129.6K2026-09-03 · Sean Saint filed to sell $327.5K2026-09-03 · Steven Jon Russell filed to sell $82.0K2026-06-29 · Stephen Feider filed to sell $83.4K2026-06-26 · Stephen Feider filed to sell $87.0K2026-06-24 · Mark Hopman filed to sell $18.8K2026-06-24 · CHRISTINA JONES filed to sell $19.2K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns BBNX: institutional holders (13F)

13F holdings, latest reported quarter
EVENTIDE ASSET MANAGEMENT, LLC
6,253,673 sh
$98.1M
Soleus Capital Management, L.P.
4,393,714 sh
$68.8M
MORGAN STANLEY
4,266,822 sh
$66.9M
Sands Capital Alternatives, LLC
3,708,043 sh
$58.1M
BlackRock, Inc.
3,340,171 sh
$52.3M

Congress trades in BBNX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

BBNX planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
MARK HOPMAN
Filed 2026-10-01
$50.5K
CHRISTINA JONES
Filed 2026-09-22
$197.1K
MARK HOPMAN
Filed 2026-09-16
$540.7K
MICHAEL MENSINGER
Filed 2026-09-16
$101.9K
MARK HOPMAN
Filed 2026-09-09
$779.1K

BBNX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
BRUCE FUND
$10.4M position · as of 2026-06-30
2.8%
Eventide Exponential Technologies Fund
$2.7M position · as of 2026-06-30
2.6%
Eventide Gilead Fund
$62.4M position · as of 2026-06-30
1.8%
Eventide Healthcare & Life Sciences Fund
$32.2M position · as of 2026-06-30
1.8%
State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF
$1.9M position · as of 2026-06-30
1.2%
Harbor Active Small Cap Growth ETF
$93.2K position · as of 2026-07-31
0.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $3.8M sold by insiders over 180 days, 87 funds added last quarter, $2.5M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

BBNX financials

Revenue growth
+53.9%
XBRL, annual
Net margin
-73.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$119.0M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-61.3%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$61.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-26.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-23.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-28.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-6.4%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Revenue$100.3M$65.1M$12.0M
Gross profit$55.5M$35.9M$6.3M
Operating income-$71.7M-$45.3M-$35.9M
Net income-$73.2M-$54.8M-$44.1M
EPS (diluted)-1.81-8.60-8.31
Operating cash flow-$50.9M-$48.3M-$32.4M
Cash$31.6M$30.4M$26.6M
SEC XBRL, fiscal years, as known on 2026-10-28

BBNX Stock Sonar score 5/7 axes

Find similar shapesCompare

BBNX ranks highest on growth (88th percentile) and institutional and government (61st), and lowest on insider conviction (16th), among Medical Devices peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
44
Inputs
  • Return on equity-26.2% · 47 pct, sector of 183
  • Return on assets-23.5% · 44 pct, sector of 214
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-28.8% · 41 pct, sector of 188
Growth
88
Inputs
  • Revenue growth, YoY+53.9% · 88 pct, sector of 219
  • Backlog growth, YoY+72.7% · 89 pct, sector of 37
Insider conviction
16
Inputs
  • Net Form 4 buying (codes P and S), 180d-$1.5M · 32 pct, sector of 140
  • Insider buyers, 180d0 · 0 pct, sector of 142
Institutional and government
61
Inputs
  • Funds adding, latest quarter87 · 61 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
27
Inputs
  • Short interest, % of float+19.4% · 4 pct, sector of 240
  • Recalls per $1B revenue, 3y29.92 per $1B · 7 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+7.2% · 71 pct, sector of 198
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

BBNX filings, in plain words

Are Beta Bionics insiders buying or selling BBNX?

In the 180 days to 2026-10-28, Beta Bionics insiders were net sellers, a net $3.8M across purchases and sales reported on Form 4, by 7 sellers.

Are there planned insider sales of BBNX?

Yes. 11 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $2.5M of stock; the latest, by MARK HOPMAN, was filed 2026-10-01.

Read the full summary

In the 180 days to 2026-10-28, Beta Bionics insiders were net sellers of BBNX, a net $3.8M across purchases and sales reported on Form 4 by 7 sellers. 25% of the 28 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 11 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $2.5M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies